Everolimus
Neuroendocrine Tumor Grade 1
AC Camargo Cancer CenterSmall moleculePhase 2Active
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 89/ 100
Competitive context
2 Active assets in the Neuroendocrine Tumor Grade 1 cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Oxodotreotide Vanderbilt-Ingram Cancer Center | Phase 4 | BB |
Octreotide Pamoate National Cancer Institute (NCI) | Phase 2 | B |
Tak-228 National Cancer Institute (NCI) | Phase 2 | B |
[212pb] vmt-α-net David Bushnell | Early Phase 1 | C |
Same molecule, other indications
Everolimus is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →